cagrilintide mixed with retatrutide Reta/Cagri Blend – 12.5mg/2.5mg Cagrilintide vs retatrutide: amylin analogue

It is critical to understand what BPC-157 is NOT: It is not an FDA-approved drug

doi: 10.1186/1472-6882-12-45 28

Standard Cagrilintide Monotherapy Chart CAGRILINTIDE ESCALATION PROTOCOL Week 1-4: [0.6 mg] Tolerance Assessment Week 5-8: [1.2 mg] Efficacy & Safety Review Week 9+: [2.4 mg] Maintenance Monitoring Theoretical Combination Dosing Chart For cagrilintide dosage with tirzepatide , a theoretical combination chart might look like: COMBINATION PROTOCOL (THEORETICAL) TIRZEPATIDE CAGRILINTIDE Week 1-4: 2.5 mg None Week 5-8: 5.0 mg None Week 9-12: 7.5 mg None Week 13-16: 7.5 mg 0.6 mg Introduction Week 17-20: 10 mg 1.2 mg Week 21+: 12.5 mg 2.4 mg Optimization This staged approach minimizes the risk of overwhelming gastrointestinal side effects while allowing for individualized dose optimization

Availability: In stock BPC 157 5mg BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide (15 amino acids) originally derived from a protein found in human gastric juice